Enliven Therapeutics, Inc. ELVN R2KR3KPHARMA
Company Overview
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.07.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +196.82% |
| 6 Months: | +101.49% |
| 3 Months: | +70.90% |
| 1 Month: | -1.58% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)56.18 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ELVN Enliven Therapeutics, Inc. R2KR3KPHARMA | 59.32 | -35.95 | $4.35B | 0.00% | -26.04% | -26.64% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 31.69M | 28.58M | 25.10M | 34.28M | 27.82M | - |
| Operating Income | -4.19M | -5.56M | -6.88M | -7.35M | -10.30M | -12.49M | -10.28M | -13.17M | -13.66M | -8.68M | -9.02M | -10.93M | -16.42M | -20.13M | -24.25M | -25.99M | -24.60M | -27.07M | - | -31.69M | -28.58M | -25.10M | -34.28M | -27.82M | -37.21M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -31.62M | -28.50M | -25.03M | -34.24M | -27.81M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -28.54M | -25.34M | -20.15M | -29.67M | -23.63M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | 0 | 0 | 0 | - | - |
| Net Income | -4.19M | -5.40M | -6.62M | -7.21M | -10.20M | -12.42M | -10.26M | -13.16M | -13.65M | -8.67M | -8.89M | -10.55M | -14.72M | -16.72M | -20.77M | -22.74M | -19.95M | -23.16M | - | -28.54M | -25.34M | -20.15M | -29.67M | -23.63M | -32.48M |
| Diluted EPS | - | - | - | - | - | - | - | -0.74 | -0.74 | -3.01 | -2.86 | -3.27 | -0.80 | -0.41 | -0.51 | -0.54 | -0.41 | -0.48 | - | -0.57 | -0.49 | -0.32 | -0.48 | -0.38 | -0.49 |
| R&D Expense | 3.56M | 4.37M | 5.14M | 5.79M | 7.87M | 9.53M | 7.12M | 10.07M | 10.40M | 7.06M | 7.94M | 7.83M | 11.88M | 15.18M | 19.61M | 19.97M | 18.83M | 21.26M | - | 24.89M | 21.49M | 18.23M | - | 20.69M | 29.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 38.79M | 83.53M | 104.55M | 119.66M |
| Operating Income | -24.12M | -41.70M | -51.44M | -38.79M | -83.53M | -104.55M | -119.66M |
| EBITDA | - | - | - | -38.58M | -83.23M | -104.24M | -119.39M |
| Interest Expense | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | -37.66M | -71.58M | -88.79M | -103.69M |
| Tax Provision | - | - | - | - | 0 | 232.00K | 0 |
| Net Income | -23.46M | -41.36M | -51.38M | -37.66M | -71.58M | -89.02M | -103.69M |
| Diluted EPS | - | - | -2.37 | -0.92 | -2.01 | -1.89 | -1.83 |
| R&D Expense | 19.01M | 32.15M | 38.44M | 31.02M | 64.57M | 80.78M | 85.86M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 33.30M | 90.84M | 93.65M | 83.30M | 271.87M | 325.76M | 476.17M |
| Total Equity | -26.32M | -48.85M | 84.44M | -42.89M | -76.83M | 245.91M | 309.85M | 459.60M |
| Cash & Equivalents | - | 4.94M | 47.70M | 48.31M | 75.54M | 100.14M | 124.12M | 98.90M |
| Total Liabilities | - | 4.38M | 6.41M | 7.62M | 10.37M | 25.96M | 15.91M | 16.57M |
| Current Liabilities | - | 4.20M | 6.25M | 7.21M | 9.71M | 25.89M | 15.91M | 16.57M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -21.88M | -37.40M | -46.77M | -32.08M | -61.27M | -73.19M | -70.30M |
| Investing Cash Flow | -24.06M | -16.72M | -1.63M | -612.00K | -148.41M | -36.00M | -173.84M |
| Financing Cash Flow | 43.58M | 96.88M | 49.10M | -1.80M | 234.29M | 133.16M | 218.87M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | 48.0% | -49.0% | 119.8% | 49.0% | -29.1% | -28.7% | -22.6% |
| ROCE % | -82.9% | -49.3% | -59.5% | -52.7% | -34.0% | -33.7% | -26.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 13.68% | 10.03M | $580.05M |
| 2 | Orbimed Advisors LLC. | 9.25% | 6.78M | $392.10M |
| 3 | Polar Capital Holdings PLC | 8.78% | 6.43M | $372.08M |
| 4 | Blackrock Inc. | 5.95% | 4.36M | $252.25M |
| 5 | Vestal Point Capital, LP | 5.46% | 4.00M | $231.44M |
| 6 | Commodore Capital Lp | 4.47% | 3.27M | $189.49M |
| 7 | Price (T.Rowe) Associates Inc | 3.96% | 2.90M | $168.02M |
| 8 | Vanguard Capital Management LLC | 3.51% | 2.57M | $148.64M |
| 9 | Citadel Advisors Llc | 2.82% | 2.07M | $119.71M |
| 10 | Fairmount Funds Management LLC | 2.53% | 1.86M | $107.37M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ELVN
Planned stock sale at Enliven Therapeutics (NASDAQ: ELVN) tops the million-dollar mark - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxOOWlTUmxMS3BzcDU4ZTZxUGx2MVgyOTBacjFiNHZINnR2dXQ5ekNsc2R5TnZxU3NRUXVBM0NqTG1GMUpEZVVtdzRka0VPMG45dUNlYWlfSDVFWlJ6RWlTSWt6dUhaNXFwLXdzenhPUkZtSTdHTkZ5Y0djM3ZScFhLdzBxMHY0b0cxbVF4Tm…
Enliven Therapeutics (ELVN) Stock Price, News & Analysis - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiWkFVX3lxTE5DZWpXTUo1MlVBTVd5RUdIeXppeDlXcUxFbHlNZXFqNnZQaGNQT2hYQzdEdHdRcEhnQWd2MDNnR1hoNlowX2g0cEYzVTNrM0dZbXhIUXl6TWhWZw?oc=5" target="_blank">Enliven Therapeutics (ELVN) Stock Price, News…
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi1wJBVV95cUxPSWZ3TkoxUDN0bjVMZnNCdXhGejBxWXZCS0I5NnpHRGhvOFVDdjJJa19IamYyWDktZ1BJanl5VldXNTlWdHhVQ3Q1akhnZFA3RXdLamVDZ1dEWnowVS1Da2pKWmF6cUg3QUdWbzk2YzlzMUgwWEt5QzUxT1BONWgybEdSaWFScENGRExiMH…
Enliven Therapeutics (ELVN) Stock Looks Overvalued As Returns Surge But Book Value Lags - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQSmUyaExTdlp0YzVEQUhncjVoeTNiRTR6cDJUalY2WUdwMk9KRUF6bGpMMk14aWlUU3Bud2FWbzFFaGRCRWhsMUdhZUtTWVg0bHlfVkZMVm5HZGF2dVJTemQ0RGFJSExrM3RnV3BQdzRMVDJRNWNnYkdRVFdNb3I0NEx0eFZsb3VyY1pIOD…
Enliven Therapeutics (ELVN) As ENABLE Data Return Puts Its 4.8x P B In Focus - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxOd212NGs0aTJlM3JLRU1nOGZ2ZXdIcE5senIzaVcyd3RyNVRTMG45M0swbHdCVjE5RW15VG95b28yVXZWSmc3dDB0M3VrWW9uS21kNG0xX3VNTEdEanIwNkJYcVlWRTFNNW1HRGFVWEhFTEUtRURVaFRpdnBvOTZpdG1fU05PWlpjQ1A0cH…
Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing (NASDAQ:ELVN) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxNd3E0Q21TSVhwUjZkaVdPTmtacXhQbmF4cW15VWZ6VWZtSm56RUItZFV1SnpKZFo0b3JuNTdNaXFDZEMtbUlRYmlZV3dIRTVhVW05N2Joc05HYXpnNFpMV1dIUXpkTUxLblFCZUZQQ1lMWl81Q2ItZ2dQSDNuVEN6dHAyUmRsakQ5b2FsUU…
ELVN — Frequently Asked Questions
What is the current share price of Enliven Therapeutics, Inc. (ELVN)?
As of 2026-09-07 16:24 PDT, Enliven Therapeutics, Inc. (ELVN) trades at $59.32 on NasdaqGS. Its 52-week range is $15.14 to $61.15.
What is the market capitalisation of ELVN?
Enliven Therapeutics, Inc. (ELVN) has a market capitalisation of $4.35B on NasdaqGS.
What is the P/E ratio of ELVN?
ELVN trades at a trailing price-to-earnings (P/E) ratio of -35.95. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 8.12.
What is the return on equity (ROE) of ELVN?
ELVN has a return on equity (ROE) of -26.64%. Its return on capital employed (ROCE) is -26.04%.
Is ELVN a good stock to buy?
This page provides a data-driven analysis of Enliven Therapeutics, Inc. (ELVN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.